The Experts below are selected from a list of 315 Experts worldwide ranked by ideXlab platform
Li Yang - One of the best experts on this subject based on the ideXlab platform.
-
Sweroside ameliorates nafld in high fat diet induced obese mice through the regulation of lipid metabolism and inflammatory response
Journal of Ethnopharmacology, 2020Co-Authors: Qiaoling Yang, Junting Gong, Zhengtao Wang, Ping Ding, Rongrong Cheng, Jinmei Li, Renchao Tong, Lili Ding, Wendong Huang, Li YangAbstract:Abstract Ethnopharmacological relevance Sweroside, an iridoid derived from Traditional Chinese Medicine, is an active component in Swertia pseudochinensis Hara. Swertia pseudochinensis Hara is first recorded in “Inner Mongolia Chinese Herb Medicine”and is considered as a folk medicine for treating hepatitis in northern China. Aim of the study: This study sought to elucidate the role of Sweroside in high fat diet induced obesity and fatty liver by using mouse model and investigated the primary molecular mechanism via transcriptomics analysis. Materials and methods C57BL/6 mice were fed high-fat diet (HFD) for 14 weeks to induce obesity, hyperglycemia, and fatty liver. These mice were subsequently treated with HFD alone or mixed with Sweroside (at a daily dosage of 60 mg per kg of BW, 120 mg per kg of BW and 240 mg per kg of BW) for 6 weeks. BW and food intake was monitored weekly. Biochemical and pathological analysis were conducted to investigate the effect of Sweroside on NAFLD. RNA-sequence and RT-qPCR analysis were performed to analyze the potential mechanism. Results The mice treated with Sweroside were resistant to HFD-induced body weight gain, insulin resistance and hepatic steatosis. Ingenuity pathway analysis (IPA) demonstrated that hepatic gene networks related to lipid metabolism and inflammatory response were down-regulated in the HFD + Sweroside group. PPAR-ɑ was located in the center of the hepatic gene network, and the significantly altered genes were CD36 and FGF21, which are related to hepatic inflammation and lipid metabolism. Consistently, upstream-regulators analysis revealed that the main enriched upstream-regulator was PPAR-ɑ. Conclusion Our results indicate that Sweroside may ameliorate obesity with fatty liver via the regulation of lipid metabolism and inflammatory responses. The beneficial effects of Sweroside might be closely associated with the regulation of PPAR-α.
-
Sweroside ameliorated carbon tetrachloride ccl4 induced liver fibrosis through fxr mir 29a signaling pathway
Journal of Natural Medicines, 2020Co-Authors: Junting Gong, Fan Yang, Qiaoling Yang, Xiaowen Tang, Lieming Xu, Zhengtao Wang, Li YangAbstract:To date, there are very few effective drugs for liver fibrosis treatment; therefore, it is urgent to develop novel therapeutic targets and approaches. In the present research, we sought to study the protective effect of Sweroside contained in Lonicera japonica or blue honeysuckle berries in a mouse model of liver fibrosis and investigate the underlying mechanism. The mouse model of liver fibrosis in was induced by intraperitoneal injections of 10% CCl4 for 6 weeks (three times/week). At the beginning of the fourth week, Sweroside was intragastrically administered once a day and at the end of the treatment, biochemical and histological studies were investigated. The expression of FXR, miR-29a and the downstream targets were analyzed as well. Moreover, the effect of Sweroside on cell proliferation was observed in human hepatic stellate cells (HSCs) (LX-2), along with using the siRNA for FXR and miR-29a inhibitor to investigate the underpinning of the anti-fibrotic effect of Sweroside. Sweroside successfully protected the liver fibrosis in CCl4-induced mouse model, accompanied by miR-29a induction. Furthermore, Sweroside also induced miR-29a in HSCs, resulting in the inhibition of COL1 and TIMP1. Our data also showed that either silencing miR-29a or knockdown of FXR in LX-2 cell abolished the inhibition of COL1 and TIMP1 as well as the inhibition of cell proliferation by Sweroside treatment. In conclusion, Sweroside exerted its anti-fibrotic effect in vivo and in vitro by up-regulation of miR-29a and repression of COL1 and TIMP1, which was at least in part through FXR.
-
Sweroside ameliorates α naphthylisothiocyanate induced cholestatic liver injury in mice by regulating bile acids and suppressing pro inflammatory responses
Acta Pharmacologica Sinica, 2016Co-Authors: Qiaoling Yang, Junting Gong, Fan Yang, Xiaowen Tang, Zhengtao Wang, Li Yang, Guangyun WangAbstract:Sweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses
-
characterization of metabolites of Sweroside in rat urine using ultra high performance liquid chromatography combined with electrospray ionization quadrupole time of flight tandem mass spectrometry and nmr spectroscopy
Journal of Mass Spectrometry, 2014Co-Authors: Wenliang Zeng, Chunyong He, S. W. Annie Bligh, Li Yang, Zhengtao WangAbstract:Sweroside, a major active iridoid in Swertia pseudochinensis Hara, is recognized as an effective agent in the treatment of liver injury. Based on previous reports, the relatively short half-life (64 min) and poor bioavailability (approximately 0.31%) in rats suggested that not only Sweroside itself but also its metabolites could be responsible for the observed hepato-protective effect. However, few studies have been carried out on the metabolism of Sweroside. Therefore, the present study aimed at identifying the metabolites of Sweroside in rat urine after a single oral dose (100 mg/kg). With ultra-high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (UHPLC/Q-TOF-MS), the metabolic profile revealed 11 metabolites in rat urine, including phase I, phase II and aglycone-related products. The chemical structures of metabolites were proposed based on accurate mass measurements of protonated or deprotonated molecules and their fragmentation patterns. Our findings showed that the aglycone of Sweroside (M05) and its glucuronide conjugate (M06) were principal circulating metabolites in rats. While several other metabolic transformations, occurring via reduction, N-heterocyclization and N-acetylation after deglycosylation, were also observed. Two metabolites (M05 and M06) were isolated from the rat urine for structural elucidation and identifcation of reaction sites. Both M05 and M06 were characterized by 1H, 13C and two-dimensional nuclear magnetic resonance (NMR) spectroscopy. UHPLC/Q-TOF-MS analysis has provided an important analytical platform to gather metabolic profile of Sweroside.
Zhengtao Wang - One of the best experts on this subject based on the ideXlab platform.
-
Sweroside ameliorates nafld in high fat diet induced obese mice through the regulation of lipid metabolism and inflammatory response
Journal of Ethnopharmacology, 2020Co-Authors: Qiaoling Yang, Junting Gong, Zhengtao Wang, Ping Ding, Rongrong Cheng, Jinmei Li, Renchao Tong, Lili Ding, Wendong Huang, Li YangAbstract:Abstract Ethnopharmacological relevance Sweroside, an iridoid derived from Traditional Chinese Medicine, is an active component in Swertia pseudochinensis Hara. Swertia pseudochinensis Hara is first recorded in “Inner Mongolia Chinese Herb Medicine”and is considered as a folk medicine for treating hepatitis in northern China. Aim of the study: This study sought to elucidate the role of Sweroside in high fat diet induced obesity and fatty liver by using mouse model and investigated the primary molecular mechanism via transcriptomics analysis. Materials and methods C57BL/6 mice were fed high-fat diet (HFD) for 14 weeks to induce obesity, hyperglycemia, and fatty liver. These mice were subsequently treated with HFD alone or mixed with Sweroside (at a daily dosage of 60 mg per kg of BW, 120 mg per kg of BW and 240 mg per kg of BW) for 6 weeks. BW and food intake was monitored weekly. Biochemical and pathological analysis were conducted to investigate the effect of Sweroside on NAFLD. RNA-sequence and RT-qPCR analysis were performed to analyze the potential mechanism. Results The mice treated with Sweroside were resistant to HFD-induced body weight gain, insulin resistance and hepatic steatosis. Ingenuity pathway analysis (IPA) demonstrated that hepatic gene networks related to lipid metabolism and inflammatory response were down-regulated in the HFD + Sweroside group. PPAR-ɑ was located in the center of the hepatic gene network, and the significantly altered genes were CD36 and FGF21, which are related to hepatic inflammation and lipid metabolism. Consistently, upstream-regulators analysis revealed that the main enriched upstream-regulator was PPAR-ɑ. Conclusion Our results indicate that Sweroside may ameliorate obesity with fatty liver via the regulation of lipid metabolism and inflammatory responses. The beneficial effects of Sweroside might be closely associated with the regulation of PPAR-α.
-
Sweroside ameliorated carbon tetrachloride ccl4 induced liver fibrosis through fxr mir 29a signaling pathway
Journal of Natural Medicines, 2020Co-Authors: Junting Gong, Fan Yang, Qiaoling Yang, Xiaowen Tang, Lieming Xu, Zhengtao Wang, Li YangAbstract:To date, there are very few effective drugs for liver fibrosis treatment; therefore, it is urgent to develop novel therapeutic targets and approaches. In the present research, we sought to study the protective effect of Sweroside contained in Lonicera japonica or blue honeysuckle berries in a mouse model of liver fibrosis and investigate the underlying mechanism. The mouse model of liver fibrosis in was induced by intraperitoneal injections of 10% CCl4 for 6 weeks (three times/week). At the beginning of the fourth week, Sweroside was intragastrically administered once a day and at the end of the treatment, biochemical and histological studies were investigated. The expression of FXR, miR-29a and the downstream targets were analyzed as well. Moreover, the effect of Sweroside on cell proliferation was observed in human hepatic stellate cells (HSCs) (LX-2), along with using the siRNA for FXR and miR-29a inhibitor to investigate the underpinning of the anti-fibrotic effect of Sweroside. Sweroside successfully protected the liver fibrosis in CCl4-induced mouse model, accompanied by miR-29a induction. Furthermore, Sweroside also induced miR-29a in HSCs, resulting in the inhibition of COL1 and TIMP1. Our data also showed that either silencing miR-29a or knockdown of FXR in LX-2 cell abolished the inhibition of COL1 and TIMP1 as well as the inhibition of cell proliferation by Sweroside treatment. In conclusion, Sweroside exerted its anti-fibrotic effect in vivo and in vitro by up-regulation of miR-29a and repression of COL1 and TIMP1, which was at least in part through FXR.
-
Sweroside ameliorates α naphthylisothiocyanate induced cholestatic liver injury in mice by regulating bile acids and suppressing pro inflammatory responses
Acta Pharmacologica Sinica, 2016Co-Authors: Qiaoling Yang, Junting Gong, Fan Yang, Xiaowen Tang, Zhengtao Wang, Li Yang, Guangyun WangAbstract:Sweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses
-
characterization of metabolites of Sweroside in rat urine using ultra high performance liquid chromatography combined with electrospray ionization quadrupole time of flight tandem mass spectrometry and nmr spectroscopy
Journal of Mass Spectrometry, 2014Co-Authors: Wenliang Zeng, Chunyong He, S. W. Annie Bligh, Li Yang, Zhengtao WangAbstract:Sweroside, a major active iridoid in Swertia pseudochinensis Hara, is recognized as an effective agent in the treatment of liver injury. Based on previous reports, the relatively short half-life (64 min) and poor bioavailability (approximately 0.31%) in rats suggested that not only Sweroside itself but also its metabolites could be responsible for the observed hepato-protective effect. However, few studies have been carried out on the metabolism of Sweroside. Therefore, the present study aimed at identifying the metabolites of Sweroside in rat urine after a single oral dose (100 mg/kg). With ultra-high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (UHPLC/Q-TOF-MS), the metabolic profile revealed 11 metabolites in rat urine, including phase I, phase II and aglycone-related products. The chemical structures of metabolites were proposed based on accurate mass measurements of protonated or deprotonated molecules and their fragmentation patterns. Our findings showed that the aglycone of Sweroside (M05) and its glucuronide conjugate (M06) were principal circulating metabolites in rats. While several other metabolic transformations, occurring via reduction, N-heterocyclization and N-acetylation after deglycosylation, were also observed. Two metabolites (M05 and M06) were isolated from the rat urine for structural elucidation and identifcation of reaction sites. Both M05 and M06 were characterized by 1H, 13C and two-dimensional nuclear magnetic resonance (NMR) spectroscopy. UHPLC/Q-TOF-MS analysis has provided an important analytical platform to gather metabolic profile of Sweroside.
Wenliang Zeng - One of the best experts on this subject based on the ideXlab platform.
-
characterization of metabolites of Sweroside in rat urine using ultra high performance liquid chromatography combined with electrospray ionization quadrupole time of flight tandem mass spectrometry and nmr spectroscopy
Journal of Mass Spectrometry, 2014Co-Authors: Wenliang Zeng, Chunyong He, S. W. Annie Bligh, Li Yang, Zhengtao WangAbstract:Sweroside, a major active iridoid in Swertia pseudochinensis Hara, is recognized as an effective agent in the treatment of liver injury. Based on previous reports, the relatively short half-life (64 min) and poor bioavailability (approximately 0.31%) in rats suggested that not only Sweroside itself but also its metabolites could be responsible for the observed hepato-protective effect. However, few studies have been carried out on the metabolism of Sweroside. Therefore, the present study aimed at identifying the metabolites of Sweroside in rat urine after a single oral dose (100 mg/kg). With ultra-high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (UHPLC/Q-TOF-MS), the metabolic profile revealed 11 metabolites in rat urine, including phase I, phase II and aglycone-related products. The chemical structures of metabolites were proposed based on accurate mass measurements of protonated or deprotonated molecules and their fragmentation patterns. Our findings showed that the aglycone of Sweroside (M05) and its glucuronide conjugate (M06) were principal circulating metabolites in rats. While several other metabolic transformations, occurring via reduction, N-heterocyclization and N-acetylation after deglycosylation, were also observed. Two metabolites (M05 and M06) were isolated from the rat urine for structural elucidation and identifcation of reaction sites. Both M05 and M06 were characterized by 1H, 13C and two-dimensional nuclear magnetic resonance (NMR) spectroscopy. UHPLC/Q-TOF-MS analysis has provided an important analytical platform to gather metabolic profile of Sweroside.
-
Characterization of metabolites of Sweroside in rat urine using ultra-high-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry and NMR spectroscopy
Journal of Mass Spectrometry, 2014Co-Authors: Han Han, Wenliang Zeng, Chunyong He, Qing Liu, S. W. Annie Bligh, Liu Yang, Z.z. WangAbstract:Sweroside, a major active iridoid in Swertia pseudochinensis Hara, is recognized as an effective agent in the treatment of liver injury. Based on previous reports, the relatively short half-life (64min) and poor bioavailability (approximately 0.31%) in rats suggested that not only Sweroside itself but also its metabolites could be responsible for the observed hepato-protective effect. However, few studies have been carried out on the metabolism of Sweroside. Therefore, the present study aimed at identifying the metabolites of Sweroside in rat urine after a single oral dose (100mg/kg). With ultra-high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (UHPLC/Q-TOF-MS), the metabolic profile revealed 11 metabolites in rat urine, including phase I, phase II and aglycone-related products. The chemical structures of metabolites were proposed based on accurate mass measurements of protonated or deprotonated molecules and their fragmentation patterns. Our findings showed that the aglycone of Sweroside (M05) and its glucuronide conjugate (M06) were principal circulating metabolites in rats. While several other metabolic transformations, occurring via reduction, N-heterocyclization and N-acetylation after deglycosylation, were also observed. Two metabolites (M05 and M06) were isolated from the rat urine for structural elucidation and identifcation of reaction sites. Both M05 and M06 were characterized by H-1, C-13 and two-dimensional nuclear magnetic resonance (NMR) spectroscopy. UHPLC/Q-TOF-MS analysis has provided an important analytical platform to gather metabolic profile of Sweroside. Copyright (c) 2014 John Wiley & Sons, Ltd.
Z.z. Wang - One of the best experts on this subject based on the ideXlab platform.
-
Characterization of metabolites of Sweroside in rat urine using ultra-high-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry and NMR spectroscopy
Journal of Mass Spectrometry, 2014Co-Authors: Han Han, Wenliang Zeng, Chunyong He, Qing Liu, S. W. Annie Bligh, Liu Yang, Z.z. WangAbstract:Sweroside, a major active iridoid in Swertia pseudochinensis Hara, is recognized as an effective agent in the treatment of liver injury. Based on previous reports, the relatively short half-life (64min) and poor bioavailability (approximately 0.31%) in rats suggested that not only Sweroside itself but also its metabolites could be responsible for the observed hepato-protective effect. However, few studies have been carried out on the metabolism of Sweroside. Therefore, the present study aimed at identifying the metabolites of Sweroside in rat urine after a single oral dose (100mg/kg). With ultra-high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (UHPLC/Q-TOF-MS), the metabolic profile revealed 11 metabolites in rat urine, including phase I, phase II and aglycone-related products. The chemical structures of metabolites were proposed based on accurate mass measurements of protonated or deprotonated molecules and their fragmentation patterns. Our findings showed that the aglycone of Sweroside (M05) and its glucuronide conjugate (M06) were principal circulating metabolites in rats. While several other metabolic transformations, occurring via reduction, N-heterocyclization and N-acetylation after deglycosylation, were also observed. Two metabolites (M05 and M06) were isolated from the rat urine for structural elucidation and identifcation of reaction sites. Both M05 and M06 were characterized by H-1, C-13 and two-dimensional nuclear magnetic resonance (NMR) spectroscopy. UHPLC/Q-TOF-MS analysis has provided an important analytical platform to gather metabolic profile of Sweroside. Copyright (c) 2014 John Wiley & Sons, Ltd.
S. W. Annie Bligh - One of the best experts on this subject based on the ideXlab platform.
-
characterization of metabolites of Sweroside in rat urine using ultra high performance liquid chromatography combined with electrospray ionization quadrupole time of flight tandem mass spectrometry and nmr spectroscopy
Journal of Mass Spectrometry, 2014Co-Authors: Wenliang Zeng, Chunyong He, S. W. Annie Bligh, Li Yang, Zhengtao WangAbstract:Sweroside, a major active iridoid in Swertia pseudochinensis Hara, is recognized as an effective agent in the treatment of liver injury. Based on previous reports, the relatively short half-life (64 min) and poor bioavailability (approximately 0.31%) in rats suggested that not only Sweroside itself but also its metabolites could be responsible for the observed hepato-protective effect. However, few studies have been carried out on the metabolism of Sweroside. Therefore, the present study aimed at identifying the metabolites of Sweroside in rat urine after a single oral dose (100 mg/kg). With ultra-high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (UHPLC/Q-TOF-MS), the metabolic profile revealed 11 metabolites in rat urine, including phase I, phase II and aglycone-related products. The chemical structures of metabolites were proposed based on accurate mass measurements of protonated or deprotonated molecules and their fragmentation patterns. Our findings showed that the aglycone of Sweroside (M05) and its glucuronide conjugate (M06) were principal circulating metabolites in rats. While several other metabolic transformations, occurring via reduction, N-heterocyclization and N-acetylation after deglycosylation, were also observed. Two metabolites (M05 and M06) were isolated from the rat urine for structural elucidation and identifcation of reaction sites. Both M05 and M06 were characterized by 1H, 13C and two-dimensional nuclear magnetic resonance (NMR) spectroscopy. UHPLC/Q-TOF-MS analysis has provided an important analytical platform to gather metabolic profile of Sweroside.
-
Characterization of metabolites of Sweroside in rat urine using ultra-high-performance liquid chromatography combined with electrospray ionization quadrupole time-of-flight tandem mass spectrometry and NMR spectroscopy
Journal of Mass Spectrometry, 2014Co-Authors: Han Han, Wenliang Zeng, Chunyong He, Qing Liu, S. W. Annie Bligh, Liu Yang, Z.z. WangAbstract:Sweroside, a major active iridoid in Swertia pseudochinensis Hara, is recognized as an effective agent in the treatment of liver injury. Based on previous reports, the relatively short half-life (64min) and poor bioavailability (approximately 0.31%) in rats suggested that not only Sweroside itself but also its metabolites could be responsible for the observed hepato-protective effect. However, few studies have been carried out on the metabolism of Sweroside. Therefore, the present study aimed at identifying the metabolites of Sweroside in rat urine after a single oral dose (100mg/kg). With ultra-high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (UHPLC/Q-TOF-MS), the metabolic profile revealed 11 metabolites in rat urine, including phase I, phase II and aglycone-related products. The chemical structures of metabolites were proposed based on accurate mass measurements of protonated or deprotonated molecules and their fragmentation patterns. Our findings showed that the aglycone of Sweroside (M05) and its glucuronide conjugate (M06) were principal circulating metabolites in rats. While several other metabolic transformations, occurring via reduction, N-heterocyclization and N-acetylation after deglycosylation, were also observed. Two metabolites (M05 and M06) were isolated from the rat urine for structural elucidation and identifcation of reaction sites. Both M05 and M06 were characterized by H-1, C-13 and two-dimensional nuclear magnetic resonance (NMR) spectroscopy. UHPLC/Q-TOF-MS analysis has provided an important analytical platform to gather metabolic profile of Sweroside. Copyright (c) 2014 John Wiley & Sons, Ltd.
